Atara biotherapeutics, inc. reports inducement grants under nasdaq listing rule 5635(c)(4)

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 116,550 restricted stock units of atara's common stock to five newly hired employee. these awards were approved by the compensation committee of atara's board of directors and granted under the.
ATRA Ratings Summary
ATRA Quant Ranking